Search

HHS Reorganization Removing Office of Chief Information Officer

The Department of Health and Human Services published a notice announcing the reorganization of its administrative structure, specifically removing the Office of Chief Information Officer from the organizational chart. The change is effective upon publication date. This is an internal administrative restructuring that affects the agency's chain of command and information technology governance.

ACHC Critical Access Hospital Accreditation Program Continued Approval

CMS published notice of the Accreditation Commission for Health Care Inc. (ACHC) application for continued approval of its Critical Access Hospital accreditation program under Medicare. The decision, if granted, would be effective from December 27, 2025, through December 27, 2031. This notice informs the public of the application and CMS's review process.

ACHC Medicare Hospice Accreditation Program CMS Approval

CMS published notice of approval for the Accreditation Commission for Health Care Inc. (ACHC) to continue its CMS-approved hospice accreditation program. The decision applies from November 27, 2025, through November 27, 2031. This routine approval allows ACHC to continue conducting accreditation surveys for Medicare and Medicaid-participating hospice providers.

Joint Commission Home Health Agency Accreditation Program Renewal Application

CMS published a notice seeking public comments on the Joint Commission's application for continued CMS approval of its Home Health Agency accreditation program. The Joint Commission currently holds deeming authority for Medicare and Medicaid-participating home health agencies. Comments on this accreditation renewal application must be submitted by May 4, 2026.

Center for Scientific Review Amends Meeting Notice

The NIH Center for Scientific Review issued an amended meeting notice changing the dates for the Neuromodulation and Imaging of Neuronal Circuits Study Section from April 16-17, 2026 to July 9-10, 2026. The meeting remains closed to the public. This is an administrative correction to a previously published Federal Register notice.

Board of Scientific Counselors, NIDA - Notice of Closed Meeting

The National Institutes of Health published a notice announcing a closed meeting of the Board of Scientific Counselors, NIDA, scheduled for May 12, 2026. The virtual meeting will review and evaluate personnel qualifications, performance, and competence of individual investigators under the Federal Advisory Committee Act. The meeting is closed pursuant to 5 U.S.C. 552b(c)(6) to protect personal privacy.

Human Antibodies With Anti-Lymphocyte Specificities - Licensing Availability

NIH/NIAID issued a notice announcing availability for licensing of novel human IgM antibodies (HHS Ref No. E-025-2025) developed for treating B-cell cancers and autoimmune conditions. The antibodies demonstrated effective B-cell killing at concentrations as low as 0.01 nanomolar. Inventors Dr. Ainhoa Pérez-Díez and Dr. Irini Sereti developed this technology. Companies may contact Benjamin Hurley at 240-276-5489 to pursue licensing.

NIH Center Scientific Review Closed Meetings

The National Institutes of Health Center for Scientific Review announced five closed meetings scheduled for late April 2026 to review grant applications. The meetings will address research in aging, oral/dental sciences, genetic therapies, training programs, and mental health/Alzheimer's disease interventions. Meetings are closed under Federal Advisory Committee Act exemptions to protect confidential grant information and applicant privacy.

ZIIHERA Regulatory Review Period Determination for Patent Extension

The FDA has determined the regulatory review period for ZIIHERA, a human biological product, and is publishing this notice as required by law for patent extension purposes under 21 USC 356. The determination is being forwarded to the USPTO for use in processing the patent extension application. Interested parties may submit comments on the accuracy of published dates or petition FDA regarding due diligence during the review period.

Determination of Regulatory Review Period for ENCELTO Patent Extension

The FDA has determined the regulatory review period for ENCELTO, a human biological product, and published this notice as required by law for patent extension purposes under 35 U.S.C. 156. The determination opens a public comment period through June 2, 2026, and allows petitions regarding due diligence through September 30, 2026.